Biopharma Ovid Therapeutics (NSDQ:OVID) has named MIT professor Robert Langer as the chair of its scientific advisory board.
The company focuses on rare neurological diseases.
“The neurosciences are on the cusp of a scientific and, hopefully, therapeutic revolution,” said Langer in a statement. “Ovid has an exciting approach to tackling the key questions that drive scientific research and new medicines in the central nervous system.”
Get the full story from our sister site, Drug Discovery & Development.